StockNews.com initiated coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Free Report) in a research note published on Friday morning. The firm issued a sell rating on the biotechnology company’s stock.
Aptevo Therapeutics Stock Performance
NASDAQ APVO opened at $0.39 on Friday. Aptevo Therapeutics has a 12 month low of $0.28 and a 12 month high of $26.40. The company’s 50 day moving average is $0.52 and its two-hundred day moving average is $2.79.
Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($9.95) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($14.10) by $4.15. Equities research analysts forecast that Aptevo Therapeutics will post -8.86 earnings per share for the current fiscal year.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Featured Stories
- Five stocks we like better than Aptevo Therapeutics
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- 3 Fintech Stocks With Good 2021 Prospects
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- What does consumer price index measure?
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
